Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Phase 3

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Biological: Placebo matching Ipilimumab
Biological: Ipilimumab
Drug: Etoposide
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2011-10-12

Last Posted Date: 2020-07-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1351

Registration Number: NCT01450761

Locations: 🇺🇸
University Of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University Hospitals, Cleveland, Ohio, United States
🇺🇸
Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States

and more 40 locations

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Phase 1

Completed

Conditions: Gamma Delta Hepatosplenic T-Cell Lymphoma
NK T-Cell Lymphoma
T-Cell Peripheral Lymphoma
Subcutaneous Panniculitis-Like T-Cell Lymphoma

Interventions: Biological: Rituximab
Drug: Etoposide
Biological: Siplizumab
Drug: Prednisone
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Doxorubicin

First Posted Date: 2011-10-03

Last Posted Date: 2021-11-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT01445535

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

Phase 2

Completed

Conditions: Extensive Stage Small Cell Lung Carcinoma

Interventions: Drug: LY2510924
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2011-09-23

Last Posted Date: 2019-07-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 90

Registration Number: NCT01439568

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Phase 1

Withdrawn

Conditions: Large-Cell Lymphoma, Diffuse
Lymphoma, Diffuse Large-Cell
Lymphoma, Diffuse Large-Cell B-cell
Diffuse, Large B-cell Lymphoma

First Posted Date: 2011-08-12

Last Posted Date: 2019-12-17

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT01415765

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 1

Terminated

Conditions: Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy
Drug: cisplatin
Drug: etoposide

First Posted Date: 2011-08-08

Last Posted Date: 2015-11-04

Lead Sponsor: University of Washington

Target Recruit Count: 6

Registration Number: NCT01411098

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

AC220 for Children With Relapsed/Refractory ALL or AML

Phase 1

Completed

Conditions: Lymphoblastic Leukemia, Acute, Childhood
Myelogenous Leukemia, Acute, Childhood

Interventions: Drug: AC220
Drug: Cytarabine
Drug: Etoposide
Drug: Methotrexate

First Posted Date: 2011-08-08

Last Posted Date: 2022-04-04

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 24

Registration Number: NCT01411267

Locations: 🇺🇸
Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States
🇺🇸
Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸
Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States

and more 8 locations

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Not Applicable

Terminated

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Grade III Lymphomatoid Granulomatosis
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Hepatosplenic T-cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Noncutaneous Extranodal Lymphoma

Interventions: Drug: plerixafor
Biological: filgrastim
Drug: etoposide
Procedure: leukapheresis

First Posted Date: 2011-08-03

Last Posted Date: 2019-06-14

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT01408043

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Doxorubicin
Drug: Bleomycin
Drug: Vinblastine
Diagnostic Test: PET
Radiation: INRT
Drug: Dacarbazine
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Procarbazine
Drug: Prednisone

First Posted Date: 2011-07-11

Last Posted Date: 2023-06-29

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 6

Registration Number: NCT01390584

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myeloid Sarcoma
Leukemia Cutis
Myeloid Neoplasm

Interventions: Drug: Asparaginase
Drug: Daunorubicin Hydrochloride
Drug: Cytarabine
Drug: Bortezomib
Other: Laboratory Biomarker Analysis
Drug: Etoposide
Drug: Mitoxantrone Hydrochloride
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Sorafenib Tosylate

First Posted Date: 2011-06-13

Last Posted Date: 2024-10-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1645

Registration Number: NCT01371981

Locations: 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸
Albany Medical Center, Albany, New York, United States

and more 217 locations

Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT

Phase 2

Recruiting

Conditions: Medulloblastoma Recurrent
ATRT Recurrent
Ependymoma Recurrent

First Posted Date: 2011-05-19

Last Posted Date: 2024-10-21

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 100

Registration Number: NCT01356290

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy